Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 362 million yuan for 2025, representing a year-on-year increase of approximately 16.63%. The net profit attributable to the parent company reached 42.12 million yuan, showing a significant year-on-year growth of 222.20% [2][3] - The company is experiencing growth in revenue from sectors such as new materials, new energy, and pharmaceuticals, driven by a recovery in industry demand and advancements in high-end instrument manufacturing [3] - The company has maintained stable investments in product research and development, market expansion, and brand enhancement, leading to the introduction of advanced instruments like organic element analyzers and liquid chromatography instruments [3] Financial Summary - For 2025, the projected net profit attributable to the parent company is 42 million yuan, with an expected EPS of 0.49 yuan per share. The corresponding P/E ratios for 2025-2027 are 49.5, 39.4, and 32.6 times, respectively [2][6] - The company anticipates a stable gross margin of around 64.8% for 2025, with a net profit margin of 10.1% [6][7] - The company plans to establish a joint venture in the medical technology sector, focusing on innovative clinical medical devices for early cancer screening and Alzheimer's diagnosis, with a 10% ownership stake [4]
海能技术（920476）：新材料、新能源、制药等领域收入增长，2025年归母净利润同比+222%